Baidu
map

谷歌重组建母公司Alphabet,医疗健康占两席之地

2015-08-12 MedSci MedSci原创

相信大家都被今天Google重组的消息刷爆了朋友圈、微博。别着急,下面笔者就带大家来捋一捋这究竟是怎么一回事? 谷歌重组更名为Alphabet 谷歌联合创始人兼CEO Larry Page 今日,谷歌联合创始人兼CEO Larry Page在官方博客上宣布了公司重组消息。 Larry Page将与另外一位联合创始人Sergey Brin创办一家新的控股公司Alpha

相信大家都被今天Google重组的消息刷爆了朋友圈、微博。别着急,下面笔者就带大家来捋一捋这究竟是怎么一回事?

谷歌重组更名为Alphabet


谷歌联合创始人兼CEO Larry Page

今日,谷歌联合创始人兼CEO Larry Page在官方博客上宣布了公司重组消息。 Larry Page将与另外一位联合创始人Sergey Brin创办一家新的控股公司Alphabet,两人分别出任CEO与总裁职位。Alphabet将掌控一系列公司,其中最大的是谷歌。公司网站的地址也打破常规,变更为https://abc.xyz/。

也就是说,Alphabet将取代谷歌在纳斯达克上市,谷歌目前所有股份将自动转换为同等数量与权益的Alphabet股份。原先的谷歌将成为Alphabet的全资子公司,而当前高级副总裁Sandar Pichai将出任新谷歌的CEO职位。

Larry Page在谷歌官方博客上表示,Alphabet旗下将包括一系列子公司,其中最大的子公司就是新谷歌。而新谷歌的业务范围将有所缩水,与谷歌核心互联网业务相对较远的公司将划归到Alphabet内。他列举了健康领域业务的两家子公司为例:血糖监测隐形眼镜业务的Life Science以及生命延长业务的Calico。


Alphabet架构图

Alphabet旗下公司包含谷歌(包括搜索、广告、地图、Youtube视频服务和移动终端系统安卓)、Calico(抗衰老生物技术)、Nest(物联网相关)、Fiber(光纤宽带服务)、Google Ventures和Google Capital (风投和投资部门)以及Google X(无人驾驶汽车、无人机等研发部门)这七大子公司。其中医疗健康占两席!

目的何在?

Larry Page解释说,重组公司的主要目的是扩大管理范围,独立运营一些并不非常相关的业务。他会为每个子公司挑选新的强有利的CEO,确定他们的薪酬水准,而他与Sergey Brin将在所需时提供建议咨询。得益于新公司架构,谷歌两位联合创始人将更加专注于原先谷歌内部的新机遇。

“新公司命名为Alphabet是来自语言文字字母的集合,而语言是人类最为重要的创新,也是谷歌搜索的索引核心。”Larry Page如是说。同时,Alpha也有投资回报的意思,会尽力给投资者带来回报。”

而早前,Larry Page就曾说过,“谷歌不是一个传统的公司。我们不打算成为普通的‘一个公司’。”——此举果然非比寻常。推荐阅读:《谷歌风云:没有公司文化的谷歌文化

Sandar Pichai是什么来头?


新谷歌CEO Sandar Pichai

Sandar Pichai 1972年出生于印度,曾获印度印度理工学院(IIT-Kharagpur)学士学位、斯坦福大学硕士学位、宾夕法尼亚州沃顿商学院MBA。2004年加盟谷歌开始,Sandar Pichai便将产品帝国逐渐扩展到了安卓系统、搜索引擎、谷歌云存储Google Drive、基于PC的操作系统Chrome OS、地图、应用软件以及广告等业务。现在,驾驶着谷歌这台价值4440亿美元豪车的Sandar Pichai ,拿到了车钥匙。Sandar Pichai的地位仅在两位联合创始人之下。

Sandar Pichai是安卓系统的工程师,负责谷歌互联网业务的产品与工程工作。Larry Page表示,“我与Sergey Brin都对Sandar Pichai取得的进展表示非常激动……我们与董事会都认为,如今是Sandar Pichai 出任谷歌CEO职位的时候了。”

国外媒体《今日美国》报道称,Sandar Pichai 才是如今谷歌的大脑和代言人。

Alphabet的由来

Alphabet的英文意思是“字母表”。目前,谷歌的项目名称已经涵盖了英文的26个字母。看到下列谷歌旗下项目表,你就知道这个名字恰如其分。



控股公司“字母表”将在“今年晚些时候”注册,各大子公司将在2016年初开始独立报告财务状况。

彭博社的解读是,谷歌负责赚钱养家,其他业务负责改变世界。——是不是很犀利?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2048232, encodeId=46f82048232f9, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Aug 30 10:22:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779693, encodeId=4a391e7969336, content=<a href='/topic/show?id=2b30235227' target=_blank style='color:#2F92EE;'>#Alphabet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2352, encryptionId=2b30235227, topicName=Alphabet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Apr 03 06:22:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035978, encodeId=c35220359e85f, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Fri Apr 29 04:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759578, encodeId=881c1e59578a1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 20 06:22:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35569, encodeId=9dad355694a, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 17:58:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537954, encodeId=8e49153e954ee, content=<a href='/topic/show?id=68af9214410' target=_blank style='color:#2F92EE;'>#谷歌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92144, encryptionId=68af9214410, topicName=谷歌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 14 13:22:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-08-30 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2048232, encodeId=46f82048232f9, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Aug 30 10:22:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779693, encodeId=4a391e7969336, content=<a href='/topic/show?id=2b30235227' target=_blank style='color:#2F92EE;'>#Alphabet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2352, encryptionId=2b30235227, topicName=Alphabet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Apr 03 06:22:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035978, encodeId=c35220359e85f, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Fri Apr 29 04:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759578, encodeId=881c1e59578a1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 20 06:22:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35569, encodeId=9dad355694a, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 17:58:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537954, encodeId=8e49153e954ee, content=<a href='/topic/show?id=68af9214410' target=_blank style='color:#2F92EE;'>#谷歌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92144, encryptionId=68af9214410, topicName=谷歌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 14 13:22:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2048232, encodeId=46f82048232f9, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Aug 30 10:22:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779693, encodeId=4a391e7969336, content=<a href='/topic/show?id=2b30235227' target=_blank style='color:#2F92EE;'>#Alphabet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2352, encryptionId=2b30235227, topicName=Alphabet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Apr 03 06:22:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035978, encodeId=c35220359e85f, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Fri Apr 29 04:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759578, encodeId=881c1e59578a1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 20 06:22:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35569, encodeId=9dad355694a, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 17:58:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537954, encodeId=8e49153e954ee, content=<a href='/topic/show?id=68af9214410' target=_blank style='color:#2F92EE;'>#谷歌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92144, encryptionId=68af9214410, topicName=谷歌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 14 13:22:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2016-04-29 jiekemin
  4. [GetPortalCommentsPageByObjectIdResponse(id=2048232, encodeId=46f82048232f9, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Aug 30 10:22:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779693, encodeId=4a391e7969336, content=<a href='/topic/show?id=2b30235227' target=_blank style='color:#2F92EE;'>#Alphabet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2352, encryptionId=2b30235227, topicName=Alphabet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Apr 03 06:22:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035978, encodeId=c35220359e85f, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Fri Apr 29 04:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759578, encodeId=881c1e59578a1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 20 06:22:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35569, encodeId=9dad355694a, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 17:58:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537954, encodeId=8e49153e954ee, content=<a href='/topic/show?id=68af9214410' target=_blank style='color:#2F92EE;'>#谷歌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92144, encryptionId=68af9214410, topicName=谷歌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 14 13:22:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2048232, encodeId=46f82048232f9, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Aug 30 10:22:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779693, encodeId=4a391e7969336, content=<a href='/topic/show?id=2b30235227' target=_blank style='color:#2F92EE;'>#Alphabet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2352, encryptionId=2b30235227, topicName=Alphabet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Apr 03 06:22:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035978, encodeId=c35220359e85f, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Fri Apr 29 04:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759578, encodeId=881c1e59578a1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 20 06:22:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35569, encodeId=9dad355694a, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 17:58:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537954, encodeId=8e49153e954ee, content=<a href='/topic/show?id=68af9214410' target=_blank style='color:#2F92EE;'>#谷歌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92144, encryptionId=68af9214410, topicName=谷歌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 14 13:22:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-08-14 medcardio

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2048232, encodeId=46f82048232f9, content=<a href='/topic/show?id=20dc234e94' target=_blank style='color:#2F92EE;'>#Alpha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2347, encryptionId=20dc234e94, topicName=Alpha)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Aug 30 10:22:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779693, encodeId=4a391e7969336, content=<a href='/topic/show?id=2b30235227' target=_blank style='color:#2F92EE;'>#Alphabet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2352, encryptionId=2b30235227, topicName=Alphabet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Sun Apr 03 06:22:00 CST 2016, time=2016-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035978, encodeId=c35220359e85f, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Fri Apr 29 04:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759578, encodeId=881c1e59578a1, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jun 20 06:22:00 CST 2016, time=2016-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35569, encodeId=9dad355694a, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96871613250, createdName=medcardio, createdTime=Fri Aug 14 17:58:00 CST 2015, time=2015-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537954, encodeId=8e49153e954ee, content=<a href='/topic/show?id=68af9214410' target=_blank style='color:#2F92EE;'>#谷歌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92144, encryptionId=68af9214410, topicName=谷歌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Aug 14 13:22:00 CST 2015, time=2015-08-14, status=1, ipAttribution=)]
    2015-08-14 仁医06

相关资讯

追随苹果谷歌 亚马逊或大举挺入医疗健康

苹果的iPhone6再过几周就要发布了,同时其健康医疗战略也会随之浮出水面。Google也有计划,准备在健康医疗市场上大展身手。这两家公司进军医疗领域引起了人们的热议,但是另外一家科技巨头亚马逊,也会在该领域一展拳脚吗?这事可能会发生,因为据报道最近亚马逊高管和FDA(美国食品药品管理局)官员进行了一次会晤。 美国《现代医学》杂志最先透露这一消息,一个月前亚马逊领导层和FDA领导层进行了接洽,其中

谷歌推出学术指标,影响因子面临颠覆?

本文经知社学术圈授权转载,如需转载请联系知社学术圈! 谷歌学术(Google Scholar)自2004年底推出以来,受到广大学者的一致好评,影响力日益增大。与Web of Science相比,谷歌学术不仅可以免费检索,而且范围远远大于Web of Science,既包括正常的学术期刊,也涉及书籍、会议、以及各种预印本。据估计,截止至2014年5月,谷歌学术共收集1亿6千万篇学术文献,几乎

谷歌智能牙齿 有人敢用吗?

谷歌总是喜欢探索一些稀奇古怪的新技术,其中就包括人体植入电子装置。最近,这家公司在智能隐形眼镜和其他人体植入设备方面的部分专利申请就遭到了媒体的曝光。 谷歌的智能隐形眼镜专利自2012年2月就已经有过亮相,而在今年的新专利当中,他们探索了这款装置在虹膜扫描方面的可能。在新技术的支持下,这副智能隐形眼镜将可识别特定的动作,比如眨眼、闭眼或点头,并在相连的设备上执行相对应的操作。

谷歌互联网医疗布局总览

谷歌对医疗健康领域一直兴趣浓厚,据《华尔街日报》报道,2013年,谷歌风投资金只有9%流向医疗和生命科学公司,2014年该比例上升到36%, 谷歌的风险投资机构Google Ventures负责人比尔·马里斯(Bill Maris)就表示,2015年谷歌在生命科学领域将会有更多值得期待的事情发生。 2013年3月,马里斯为谷歌招募遗传学专家安德鲁·康拉德(Andrew Conrad),成为G

亚马逊和谷歌PK基因云存储市场

据《路透社》报道,亚马逊和谷歌正针对人类DNA存储数据展开较量,两家公司都希望借此帮助科学家在医学领域做出新发现,并争取在基因云存储市场中占据份额。到2018年,该市场的规模可达到每年10亿美元。 根据对研究人员、行业顾问和分析师的采访显示,学术机构和医疗公司正在谷歌的GoogleGenomics和亚马逊AWS云服务之间抉择。在备受瞩目的基因云存储领域中,这两家公司正展开激烈竞争。 基因医学发

谷歌模仿苹果,可能发布以GoogleFit为核心的智能医疗设备

距谷歌I/O开发者大会开幕还有一周时间,我们都在翘首以盼谷歌今年会发布哪些新产品。谷歌一年一度的I/O大会的目的是建立开发者网络,并且通过研讨会的形式磨练他们的技能。然而,这些会议的主要看点是谷歌的主题演讲,公司高管们将会在演讲中披露公司新的项目、新产品以及升级情况。 去年的主题演讲几乎都围绕着Android进行。我们抢先看到了Android L(Android5.0 Lollipop的

Baidu
map
Baidu
map
Baidu
map